Dear Ms. Davis:

Please refer to your supplemental new drug application dated August 25, 2005, received August 29, 2005, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Advil Allergy Sinus (200 mg ibuprofen/30 mg pseudoephedrine HCl/2 mg chlorpheniramine maleate) tablets.

We also acknowledge receipt of your submission dated November 7, 2005.

This supplemental new drug application provides for revisions to the Drug Facts label and Principal Display Panel for the 1-, 10-, and 20-count package sizes for Advil Allergy Sinus and the 10- and 30-count package sizes for Advil Multi-Symptom Cold in response to the June 14 and July 15, 2005 supplemental labeling request letters. According to your November 7, 2005 submission, the Advil Allergy Sinus 10-count package size is representative of the Advil Allergy Sinus 20-count package size and the Advil Multi-Symptom Cold 10- and 30-count package sizes.

We have completed our review of this application, as amended. This application is approved for the Advil Allergy Sinus 10-count package size, which is representative of the Advil Allergy Sinus 20-count package size and the Advil Multi-Symptom Cold 10- and 30-count package sizes, and the Advil Allergy Sinus 1-count pouch, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the submitted labeling (Advil Allergy Sinus 10-count blister card submitted August 25, 2005, Advil Allergy Sinus 10-count carton label submitted November 7, 2006, and Advil Allergy Sinus 1-count pouch submitted November 7, 2006), and must be formatted in accordance with the requirements of 21 CFR 201.66.

Please submit an electronic version of the FPL for all represented stock keeping units according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "FPL for approved supplement NDA 21-441/S-005". Approval of this submission by FDA is not required before the labeling is used.
If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
WO 22, Room 4447
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Neel Patel, Regulatory Project Manager, at (301) 796-0970.

Sincerely,

{See appended electronic signature page}

Andrea Leonard-Segal, MD
Acting Director
Division of Nonprescription Clinical Evaluation
Office of Nonprescription Products
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
Andrea Segal
2/27/2006 11:03:59 AM